Search results
Showing 436 to 450 of 2576 results for methods
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Recommendation ID NG135/6 Question What methods and techniques help secondary schools and providers to effectively engage with parents
Awaiting development Reference number: GID-TA11534 Expected publication date: TBC
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]
Awaiting development Reference number: GID-TA11744 Expected publication date: TBC
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]
Awaiting development Reference number: GID-TA11667 Expected publication date: TBC
Awaiting development Reference number: GID-TA11161 Expected publication date: TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development Reference number: GID-TA11775 Expected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: TBC
Awaiting development Reference number: GID-TA11743 Expected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Awaiting development Reference number: GID-TA11692 Expected publication date: TBC
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130]
Awaiting development Reference number: GID-TA11325 Expected publication date: TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Awaiting development Reference number: GID-TA11755 Expected publication date: TBC
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Awaiting development Reference number: GID-TA11741 Expected publication date: TBC
Awaiting development Reference number: GID-TA11753 Expected publication date: TBC